Table 2.
Characteristics of the juvenile idiopathic arthritis group (n = 42)
| Clinical characteristics | Value |
|---|---|
| Age at study visit, years, median (IQR) | 13.9 (11.3–15.1) |
| Age at disease onset, years, median (IQR) | 8.4 (2.7–11.1) |
| Disease duration, years, median (IQR) | 4.8 (2.8–8.3) |
| JIA categorya, n (%) | |
| Oligoarticular persistent | 15 (35.7) |
| Oligoarticular extended | 3 (7.1) |
| Polyarticular RF negative | 10 (23.8) |
| Psoriatic | 2 (4.8) |
| Enthesitis-related | 8 (19.0) |
| Undifferentiated | 4 (9.5) |
| ANA positiveb, n (%) | 14 (35.0) |
| HLA-B27 positive, n (%) | 13 (31.0) |
| Disease activityc, n (%) | |
| Remission off medication | 12 (28.6) |
| Inactive | 9 (21.4) |
| Active | 21 (50.0) |
| JADAS71d > 0, n (%) | 28 (70.0) |
| PhysGA VAS > 0, n (%) | 14 (33.3) |
| Number of individuals with active jointse, n (%) | 9 (21.4) |
| DMARDsf ongoing, n (%) | 24 (57.1) |
| Steroids ongoing, n (%) | 2 (4.7) |
| NSAIDs ongoing, n (%) | 15 (35.7) |
| No medication, n (%) | 13 (31.0) |
JIA juvenile idiopathic arthritis, IQR inter-quartile range, ANA antinuclear antibodies, RF Rheumatoid factor, HLA-B27 human leukocyte antigen B27, JADAS71 Juvenile Idiopathic Arthritis Activity Score based on 71 joints, VAS visual analog scale, PhysGA VAS physician’s global assessment of disease activity using a 21 numbered circle VAS (0 = no activity, 10 = maximum activity), DMARDs disease-modifying anti-rheumatic drugs, bDMARDs biologic DMARDs, NSAIDs non-steroid anti-inflammatory drugs
aAccording to the International League of Association for Rheumatology (ILAR) classification criteria. Only non-systemic JIA categories were included. No children had RF positive polyarticular JIA
b ANA positive is defined as two positive ANA tests with HEp-2 substrate measured at least 3 months apart
c Disease status according to Wallace et al. Remission off medication = inactive disease off medication for ≥ 12 months. Inactive = inactive disease on medication for < 6 months, or off medication < 12 months, or remission on medication (inactive disease on medication for ≥ 6 months). Active = continuous active disease or flare
d JADAS71 is a composite scoring tool measuring disease activity (range 0–101 0 = no activity, 101 = maximum activity), consisting of the physician’s global assessment of disease activity VAS (0–10), the parents/patient global assessment of disease impact on wellbeing VAS (0–110), the number of active joints (0–71), and the normalized erythrocyte sedimentation rate (ESR) (0–10). (2 missing)
e Number of participants with physician-determined swollen joints or joints with loss of range of motion and joint pain or tenderness
f Either synthetic (methotrexate and mycophenolate mofetil) and/or biologic (etanercept, infliximab, adalimumab, certolizumab, tocilizumab, abatacept) DMARDs